CSL investors had already torched tens of billions of dollars of wealth on the biomedical giant before the year had even started, and a sense of panic must have set in when its chief executive, Dr Paul McKenzie, abruptly resigned the day before its half-year results announcement in February.
How much worse could it get?
Trump’s war on big pharma’s pricing power in the US, and weakness on the vaccine front from COVID fatigue and vaccine scepticism from his health secretary Robert F. Kennedy Jr, had…
